Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

Metronidazole resistance in Trichomonas vaginalis from highland women in Papua New Guinea

Jacqueline A. Upcroft A B F , Linda A. Dunn A B , Tilda Wal C , Sepehr Tabrizi D , Maria G. Delgadillo-Correa E , Patricia J. Johnson E , Suzanne Garland D , Peter Siba C and Peter Upcroft A B
+ Author Affiliations
- Author Affiliations

A Queensland Institute of Medical Research, The Bancroft Centre, 300 Herston Road, Brisbane, Qld 4006, Australia.

B Australian Centre for International and Tropical Health, The University of Queensland, Brisbane, Qld 4029, Australia.

C Papua New Guinea Institute of Medical Research, PO Box 60, Goroka, EHP 441, Papua New Guinea.

D The Royal Women’s Hospital, Department of Microbiology, 132 Grattan Street, Carlton, Melbourne, Vic. 3053, Australia.

E Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles School of Medicine, 1602 Molecular Sciences Building, 405 Hilgard Avenue, Los Angeles, CA 90095-1489, USA.

F Corresponding author. Email: Jacqui.Upcroft@qimr.edu.au

Sexual Health 6(4) 334-338 https://doi.org/10.1071/SH09011
Submitted: 3 February 2009  Accepted: 21 May 2009   Published: 13 November 2009

Abstract

Background: The prevalence of the sexually transmissible protozoan parasite Trichomonas vaginalis in the highlands of Papua New Guinea (PNG) has been reported to be as high as 46% and although not previously studied in Papua New Guinea, clinical resistance against metronidazole (Mz), the drug most commonly used to treat trichomoniasis, is well documented worldwide. This study was primarily aimed at assessing resistance to Mz in T. vaginalis strains from the Goroka region. Methods: Consenting patients presenting at the Goroka Base Hospital Sexually Transmitted Diseases (STD) Clinic and local women were asked to provide two vaginal swabs: one for culturing of the parasite; and one for polymerase chain reaction detection of T. vaginalis, Chlamydia trachomatis and Neisseria gonorrhoeae. T. vaginalis isolates were assayed for Mz susceptibility and a selection was genotyped. Results: The prevalence of T. vaginalis was determined to be 32.9% by culture and polymerase chain reaction of swabs among 82 local women and patients from the STD clinic. An unexpectedly high level of in vitro Mz resistance was determined with 17.4% of isolates displaying unexpectedly high resistance to Mz. The ability to identify isolates of T. vaginalis by genotyping was confirmed and the results revealed a more homogeneous T. vaginalis population in Papua New Guinea compared with isolates from elsewhere. Conclusion: T. vaginalis is highly prevalent in the Goroka region and in vitro Mz resistance data suggest that clinical resistance may become an issue.

Additional keywords: Chlamydia trachomatis, genotyping, Neisseria gonorrhoeae, polymerase chain reaction, vaginal swab.


Acknowledgements

We thank all those involved in the collection of isolates used in this study especially Hannah Nivea of the PNGIMR, and all those from the Goroka Base Hospital. We acknowledge Lynette Corbeil of University of California, San Diego for kindly allowing us to use T. vaginalis isolates from her collection in this study. This work was made possible through the contribution and enthusiasm of the PNGIMR. It was supported by a Winston Churchill Memorial Trust Travel Fellowship to J.A.U. and by the Australian Centre for International and Tropical Health and Nutrition. The work carried out in this study was approved by the Medical Research Advisory Committee of Papua New Guinea. We acknowledge support by an NIH U01 Cooperative Research Agreement AI75527.


References


[1] Rein MF , Müller M . Trichomonas vaginalis and trichomoniasis. In: Holmes KK, editor. Sexually Transmitted Diseases. New York: McGraw-Hill; 1990. pp. 481–92.

[2] Cohen J. HIV transmission. AIDS researchers look to Africa for new insights. Science 2000; 287 942–3.
CrossRef | CAS | PubMed |

[3] Viikki M,  Pukkala E,  Nieminen P,  Hakama M. Gynaecological infections as risk determinants of subsequent cervical neoplasia. Acta Oncol 2000; 39 71–5.
CrossRef | CAS | PubMed |

[4] Upcroft P,  Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001; 14 150–64.
CrossRef | CAS | PubMed |

[5] Guenthner PC,  Secor WE,  Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun 2005; 73 4155–60.
CrossRef | CAS | PubMed |

[6] Schwebke JR,  Aira T,  Jordan N,  Jolly P,  Vermund SH. Sexually transmitted diseases in Ulaanbaatar, Mongolia. Int J STD AIDS 1998; 9 354–8.
CrossRef | CAS | PubMed |

[7] Bowden FJ,  Paterson BA,  Mein J,  Savage J,  Fairley CK,  Garland SM, et al. Estimating the prevalence of T. vaginalis, C. trachomatis, N. gonorrhoeae, and human papillomavirus infection in indigenous women in northern Australia. Sex Transm Infect 1999; 75 431–4.
CrossRef | CAS | PubMed |

[8] Mgone CS,  Lupiwa T,  Yeka W. High prevalence of Neisseria gonorrhoeae and multiple sexually transmitted diseases among rural women in the Eastern Highlands Province of Papua New Guinea, detected by polymerase reaction. Sex Transm Dis 2002; 29 775–9.
CrossRef | PubMed |

[9] Mgone CS,  Passey ME,  Anang J,  Peter W,  Lupiwa T,  Russell DM, et al. Human immunodeficiency virus and other sexually transmitted infections among female sex workers in two major cities in Papua New Guinea. Sex Transm Dis 2002; 29 265–70.
CrossRef | PubMed |

[10] Tiwara S,  Passey M,  Clegg A,  Mgone C,  Lupiwa S,  Suve N, et al. High prevalence of trichomonal vaginitis and chlamydial cervicitis among a rural population in the highlands of Papua New Guinea. P N G Med J 1996; 39 234–8.
CAS | PubMed |

[11] Sorvillo F,  Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet 1998; 351 213–4.
CrossRef | CAS | PubMed |

[12] Crowell AL,  Sanders-Lewis KA,  Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 2003; 47 1407–9.
CrossRef | CAS | PubMed |

[13] Dunne RL,  Dunn LA,  Upcroft P,  O’Donoghue PJ,  Upcroft JA. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003; 13 239–49.
CrossRef | CAS | PubMed |

[14] Upcroft JA,  Delgadillo-Correa MG,  Dunne RL,  Sturm AW,  Johnson PJ,  Upcroft P. Genotyping Trichomonas vaginalis. Int J Parasitol 2006; 36 821–8.
CrossRef | CAS | PubMed |

[15] Clark CG,  Diamond LS. Methods for cultivation of luminal parasitic protists of clinical importance. Clin Microbiol Rev 2002; 15 329–41.
CrossRef | PubMed |

[16] Upcroft JA,  Upcroft P. Drug susceptibility testing of anaerobic protozoa. Antimicrob Agents Chemother 2001; 45 1810–4.
CrossRef | CAS | PubMed |

[17] Knox J,  Tabrizi SN,  Miller P,  Petoumenos K,  Law M,  Chen S, et al. Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by polymerase chain reaction among women living in remote areas. Sex Transm Dis 2002; 29 647–54.
CrossRef | PubMed |

[18] Voolmann T,  Boreham P. Metronidazole resistant Trichomonas vaginalis in Brisbane. Med J Aust 1993; 159 490.
CAS | PubMed |

[19] Passey M,  Mgone CS,  Lupiwa S,  Suve N,  Tiwara S,  Lupiwa T, et al. Community based study of sexually transmitted diseases in rural women in the highlands of Papua New Guinea: prevalence and risk factors. Sex Transm Infect 1998; 74 120–7.
CrossRef | CAS | PubMed |

[20] Radonjic IV,  Dzamic AM,  Mitrovic SM,  Arsic Arsenijevic VS,  Popadic DM,  Kranjcic Zec IF. Diagnosis of Trichomonas vaginalis infection: The sensitivities and specificities of microscopy, culture and PCR assay. Eur J Obstet Gynecol Reprod Biol 2006; 126 116–20.
CrossRef | CAS | PubMed |



Rent Article (via Deepdyve) Export Citation Cited By (22)